Artizan’s ability to identify, characterize, and inhibit specific soluble microbial factors is applicable to a range of therapeutic areas, including certain cancers, gastrointestinal, metabolic, autoimmune, and neurodegenerative.
The company is developing a portfolio of compounds to treat inflammatory bowel disease (IBD), which is comprised of Crohn’s Disease and ulcerative colitis. IBD is a complex condition for which currently available therapies fail to address the root cause of disease. Artizan’s novel small molecules and antibodies are a paradigm shift in the treatment of IBD. Artizan has developed the first precision medicine approach to treat a chronic inflammatory condition.